Biomarker ID | 786 |
PMID | 22009027 |
Year | 2011 |
Biomarker | AMACR+CSTA+HPN+MYO6+LAMB3+ABCC4 |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated: [ABCC4, AMACR, HPN and MYO6]; Downregulated: [CSTA and LAMB3] |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Tumor Vs Normal Tissues |
Type of Biomarker | Diagnostic |
Cohort | 38 patients were biopsied for PCA. More samples for validation were further added and the final cohort had 84 samples such that 19 were non-tumoral and 65 were tumoral |
Senstivity | 88.8% |
Specificity | 96.1% |
AUC | NA |
Accuracy | 92.6% |
Level Of Significance | p<0.001 |
Method Used | Quantitative real time PCR (qRT-PCR) |
Clinical | No |
Remarks | Gene signature was created from the surplus material washed off from needle biopsies. |
Clinical Trial Number | NA |
Degree Of Validity | Validated on Independent Patient Cohort |
Technical Name | AMACR, CSTA, HPN, MYO6, LAMB3, ABCC4 |